Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 504

Sort by

Sort Order Select

Journal Articles

Outcomes of rare patients with a primary cutaneous CD30 + lymphoproliferative disorder developing extracutaneous disease

Rutger C. Melchers, Rein Willemze, Joost S. P. Vermaat, Patty M. Jansen, Laurien A. Daniëls, Hein Putter, Marcel W. Bekkenk, Ellen R. M. de Haas, Barbara Horvath, Michelle M. van Rossum, Cornelus J. G. Sanders, Joep C. J. M. Veraart, Maarten H. Vermeer, Koen D. Quint

Blood (2020) 135 (10): 769–773.

https://doi.org/10.1182/blood.2019002799

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin in the treatment of CD30 + PTCL

Stefan K. Barta, Jerald Z. Gong, Pierluigi Porcu

Blood (2019) 134 (26): 2339–2345.

https://doi.org/10.1182/blood.2019001821

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Cesar Gentille Sanchez, MD, Joe Ensor, PhD, Akshjot Puri, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Sai Ravi Kiran Pingali, MD

Blood (2019) 134 (Supplement_1): 4022.

https://doi.org/10.1182/blood-2019-131991

Published: 2019

Journal Articles

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Wenyu Shi, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 4069.

https://doi.org/10.1182/blood-2019-130063

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Blood (2019) 134 (Supplement_1): 4028.

https://doi.org/10.1182/blood-2019-130223

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS

Blood (2019) 134 (Supplement_1): 4054.

https://doi.org/10.1182/blood-2019-121523

Published: 2019

Journal Articles

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Teresa Poggio, Linda Graessel, Stefanie Kreutmair, Cornelius Miething, Dietmar Pfeifer, Geoffroy Andrieux, Melanie Boerries, Marie Follo, Suzanne Turner, Robert Zeiser, MD, Justus Duyster, MD, Anna Lena Illert

Blood (2019) 134 (Supplement_1): 2542.

https://doi.org/10.1182/blood-2019-125589

Published: 2019

Journal Articles

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Jennifer Agrusa, MD, Elmoataz A Abdel Fattah, MBBCh, Howard Lin, BS, Rikhia Chakraborty, PhD, Brooks Scull, MS, Harshal Abhyankar, MS, Nmazuo Wudo Ozuah, MBBS, Olive S. Eckstein, MD, Terzah M Horton, MD PhD, Kala Kamdar, MD, Kenneth L. McClain, MD PhD, Chris Tsz-Kwong Man, PhD, Carl E. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2773.

https://doi.org/10.1182/blood-2019-125982

Published: 2019

Journal Articles

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

Paola Ghione, MD, Peter Cordeiro, MD, Venkatraman Seshan, PhD, Natasha Galasso, Nivetha Ganesan, MPH, Qunying Hu, Ahmet Dogan, MD PhD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2842.

https://doi.org/10.1182/blood-2019-122572

Published: 2019

Journal Articles

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Nicolas Martinez-Calle, MD MSc, Amy A. Kirkwood, MSc, Maxine Lamb, PhD, Alexandra Smith, PhD, Kate Manos, Caroline Shrubsole, MD, Nicola Gray, Sapna Ladani, MRCP, Katharine Louise Lewis, BMBS, FRCPath, MRCPath, Mark Bishton, Matthew J Ahearne, MDMBBS, Eliza A Hawkes, Wendy Osborne, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Cathy Burton, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 2849.

https://doi.org/10.1182/blood-2019-122083

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD

Blood (2019) 134 (Supplement_1): 2852.

https://doi.org/10.1182/blood-2019-122968

Published: 2019

Journal Articles

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Timothy J Voorhees, MD, Natalie S Grover, MD, Anne Beaven, MD, Steven I Park, MD, J. Kaitlin Morrison, PhD, Catherine Joyce Arago Cheng, BS, Spencer Laing, BA, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3233.

https://doi.org/10.1182/blood-2019-122846

Published: 2019

Journal Articles

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

Marc Nicolas Bienz, MD MSc, Cheryl Taylor-Kashton, Naciba Benlimame, PhD, Tina Petrogiannis-Haliotis, MD PhD, Kevin Pehr, MD, Sabine Mai, PhD, Hans Knecht, MD

Blood (2019) 134 (Supplement_1): 1501.

https://doi.org/10.1182/blood-2019-124559

Published: 2019

Journal Articles

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Kirill A. Lyapichev, MD, L. Jeffrey Medeiros, MD, Shaoying Li, MD, C. Cameron Yin, MD PhD, Guilin Tang, MD, M. James You, MD PhD, Sergej Konoplev, Swaminathan P. Iyer, MD, Carlos E. Bueso-Ramos, MD PhD, Roberto N. Miranda, MD, Jie Xu

Blood (2019) 134 (Supplement_1): 1560.

https://doi.org/10.1182/blood-2019-124556

Published: 2019

Journal Articles

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Giuseppe Lia, PhD, Clara Di Vito, PhD, Marta Tapparo, PhD, Stefania Bruno, Elisa Zaghi, Michela Calvi, Lucia Brunello, Jacopo Mariotti, MD, Lorenzo Comba, Luisa Giaccone, Martina Fascì, Mario Boccadoro, Andrea Evangelista, MSc, Luca Castagna, MD, Giovanni Camussi, Domenico Mavilio, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 598.

https://doi.org/10.1182/blood-2019-126521

Published: 2019

Journal Articles

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Carmina Louise Hugo Guerrero, MS, Yoshiko Yamashita, PhD, Megumi Kuba-Miyara, PhD, Naoki Imaizumi, PhD, Shugo Sakihama, PhD, Masaki Hayashi, MD, Takashi Miyagi, MD PhD, Satoko Morishima, MD PhD, Kennosuke Karube, MD PhD, Yuetsu Tanaka, PhD, Hiroaki Masuzaki, MD PhD, Takuya Fukushima, MD PhD

Blood (2019) 134 (Supplement_1): 660.

https://doi.org/10.1182/blood-2019-129817

Published: 2019

NARROW

Outcomes of rare patients with a primary cutaneous CD30 + lymphoproliferative disorder developing extracutaneous disease

Brentuximab vedotin in the treatment of CD30 + PTCL

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only